Publications

September 1990 (Revised January 1992)
Case

Eli Lilly and Co. (A): Globalization

By: Michael Y. Yoshino

Examines the changes taking place in Eli Lilly in response to the globalization of the pharmaceuticals industry. Identifies the steps taken by management, problems currently faced, and challenges for the future. Allows examination of the process of implementing a... View Details

Keywords: Change; Globalization; Global Strategy; Business or Company Management; Problems and Challenges; Perspective; Pharmaceutical Industry

14 Jul 2021
Blog Post

From Colombia to the District of Columbia: Making an Impact with Paulina Llano (MBA 2022)

herself in Boston at Harvard Business School and is spending the summer interning for a Cambridge-based pharmaceutical and biotech company that has become a household name – Moderna. The contributions Llano will be making to the team and... View Details

Keywords: Health Care

April 2017
Supplement

Imprimis (C)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel

This case is a supplement to Imprimis (A & B). Set in 2015, it first describes Imprimis’s decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the... View Details

Keywords: Health Care and Treatment; Cost; Moral Sensibility; Competitive Strategy; Decision Choices and Conditions; Pharmaceutical Industry; United States

2010
Chapter

From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance

By: Arthur A. Daemmrich

Adverse drug reactions pose distinct but potentially catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of... View Details

Keywords: Governing Rules, Regulations, and Reforms; Health Testing and Trials; Business and Government Relations; Risk and Uncertainty; Safety; Pharmaceutical Industry; United States

Find at Harvard

04 Nov 2016
News

New war on drugs: Pharma becoming 'uninvestable'?

May 2021
Article

Private and Social Returns to R&D: Drug Development and Demographics

By: Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou and Joshua Krieger

Investment in intangible capital such as R&D has increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer... View Details

Keywords: Drug Development; Research and Development; Investment Return; Demographics; Pharmaceutical Industry

Find at Harvard

Register to Read

March 1994 (Revised March 1995)
Case

Astra/Merck Group

By: Frank V. Cespedes and Marie Bell

Astra/Merck (A/M), originally a joint venture of AB Astra and Merck & Co., is preparing to be an independent company in 1993. Since the company does not engage in basic research and development of drugs, it is essentially a distribution organization. Fundamental to... View Details

Keywords: Cost vs Benefits; Marketing Strategy; Distribution; Performance Evaluation; Research and Development; Risk and Uncertainty; Sales; Competitive Strategy; Pharmaceutical Industry

Find at Harvard

Video

Said Darwazah

Said Darwazah, Executive Chairman and CEO of Hikma Pharmaceuticals PLC, argues that transitioning to a publicly held company ensures the continuity of a previously family-owned business. View Details

26 Apr 2010
News

Pharma's Future Depends on These Three Trends

January 2011 (Revised January 2012)
Case

The Case of the Unidentified Healthcare Companies2010

By: Richard Bohmer, Ethan Bernstein, Margarita Krivitski and Srinidhi Reddy

This case presents financial statements and selected ratios for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details

Keywords: Financial Reporting; Financial Statements; Health Care and Treatment; Health Industry

January 2001
Case

Abgenix and the XenoMouse

By: Robert J. Dolan

Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details

Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry

Research Summary

Drivers of market entry

In this paper, I look at the selection of markets for entry. Specifically, regulation in the US pharmaceutical industry allows generic firms to try and enter the market prior to the expiration of patents. This work aims to understand what drives market entry,... View Details

May 2005
Case

Merck: Conflict and Change

Tracks Merck's efforts to adapt to changes in the pharmaceutical industry. Key challenges include adapting Merck's internally focused, science-led culture to a more open environment, where marketing performance has become increasingly important. Examines Merck's... View Details

Keywords: Organizational Change and Adaptation; Organizational Culture; Conflict and Resolution; Pharmaceutical Industry

January 2001
Case

Merck Global Health Initiatives (A)

By: James E. Austin, Diana Barrett and James Weber

The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details

Keywords: Programs; Philanthropy and Charitable Giving; Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Pharmaceutical Industry; Botswana